Cytiva strengthens support to diagnostics industry with new labs, services and supply chain enhancements

  • Now offering Cytiva Diagnostic Services, new diagnostic test development and support service virtually or at new lab, for point-of-care diagnostic developers to increase speed to market of new tests.
  • Supply chain enhancements include increasing inventory, investing in plants and expanding number of partner organizations.

- Cytiva launches new services for diagnostic developers and will establish new labs to meet the future needs of the industry . Cytiva Diagnostic Services will help developers bring point-of-care diagnostic tests to market quicker through infrastructure, expertise and consultation for point of care immunoassay development. A multi-million dollar investment will be used partly to expand chemistry labs in Cardiff, Wales as well as establishing design labs in Germany and China .

Cytiva has had a critical role working with diagnostic developers during the COVID-19 pandemic. In total, over 50 million people have been PCR tested using components or services from Cytiva. Diagnostic components, such as nitrocellulose membranes, are used in 18 immunoassay-based COVID-19 tests available today.

Investment in its molecular diagnostic component lab in Wales means more work with companies such as genedrive , a molecular diagnostics company. David Budd , CEO genedrive says, "Our R&D teams worked effectively together in combining their expertise, experience, and technologies to deliver innovative PCR Kits based on Cytiva's 'Ready-to-Go' formulations. The speed at which we were able to move together was facilitated by many previous years of cooperative working."

The new services will follow the same collaborative approach as Cytiva's work with Avacta . The companies are co-developing a rapid antigen test strip for COVID-19 to provide a result in minutes using patient saliva.

Alastair Smith , CEO of Avacta, comments: "Cytiva has been a key partner in developing a rapid coronavirus antigen test and we continue to work closely with them, and our manufacturing partners, to finalise the test in a format suitable for massively scaled-up manufacturing processes to meet the anticipated demand."

The new services will include training, test optimization expertise and contract development and can be hosted virtually or in person at Cytiva's new lab in Dassel, Germany . Another lab for diagnostics development work is being planned for China in 2021. These projects form part of Cytiva's 500 million USD investment over five years to expand manufacturing capacity.

Emmanuel Abate , Vice President, Genomics and Cellular Research at Cytiva, says: "We have seen a lot of new companies entering the field this year to address the challenges of the pandemic. As a diagnostic component provider with over 30 years' experience, we have a key role supporting the industry through the next series of challenges with our manufacturing and design expertise."

Join Cytiva's Diagnostics Virtual Summit
On Oct 28 Cytiva is hosting a thought-provoking and interactive virtual summit showcasing recently launched technologies, products and solutions supporting the development of diagnostics. Register here for the live event or access the playback (available for 12 months).

About Cytiva
Cytiva is a global life sciences leader with more than 7,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.

Cision View original content: https://www.prnewswire.com/news-releases/cytiva-strengthens-support-to-diagnostics-industry-with-new-labs-services-and-supply-chain-enhancements-301159514.html

SOURCE Cytiva

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Star Jones , award winning television personality & women's heart health advocate,   helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign

A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S. many women are still unaware of the risk and the importance of heart health.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×